Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug;137(Suppl 6):219-232.
doi: 10.1007/s00508-025-02582-y. Epub 2025 Jul 31.

Was kommt nach CDK4/6-Inhibition? Perspektiven beim fortgeschrittenen Mammakarzinom

[Article in German]
Vanessa Castagnaviz  1   2 , Anna Fenzl  3 , Michael Gnant  4 , Rupert Bartsch  5
Affiliations

Was kommt nach CDK4/6-Inhibition? Perspektiven beim fortgeschrittenen Mammakarzinom

[Article in German]
Vanessa Castagnaviz et al. Wien Klin Wochenschr. 2025 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Interessenkonflikt: V. Castagnaviz: Speaking Honoraria: Daiichi Sankyo, Astra Zeneca, Novartis, Roche. Adivisory board/Consulting Honoraria: Novartis, Roche, Pfizer. Travel and conference attendance: Daiichi Sankyo, Astra Zeneca, Gilead, Pierre-Fabre, Eli-Lilly, Menarini-Stemline, Roche, Novartis, Pfizer. M. Gnant: Personal fees/travel support from Amgen, AstraZeneca, Bayer, DaiichiSankyo, EliLilly, EPG Health (IQVIA), Menarini-Stemline, MSD, Novartis, PierreFabre, Veracyte. R. Bartsch: Advisory Role: Astra-Zeneca, Daiichi, Eisai, Eli-Lilly, Gilead, Gruenenthal, MSD, Novartis, Pfizer, Pierre-Fabre, Roche, Seagen, Stemline. Lecture Honoraria: Astra-Zeneca, BMS, Daichi, Eisai, Eli-Lilly, Gilead, Gruenenthal, MSD, Novartis, Pfizer, Pierre-Fabre, Roche, Seagen, Stemline. Research Support: Daiichi, MSD, Novartis, Roche. A. Fenzl gibt an, dass kein Interessenkonflikt besteht.

Figures

Abb. 1
Abb. 1
Resistenz gegenüber endokriner Therapie (ET) bei ER+/HER2− metastasiertem Mammakarzinom (mBC). Primäre endokrine Resistenz [22], sekundäre endokrine Resistenz [22], Intrinsisch [23, 24, 25], Erworben [23, 28]
Abb. 2
Abb. 2
Wirksamkeit von 2L+ ET-basierten Therapien bei HR+/HER2− mBC mit oder ohne vorangegangene CDK4/6i-Therapie. EMERALD [77]; SoFEA [78]; Rozenblit [57]; BOLERO‑2 [79]; postMONARCH [80]; MONALEESA‑3 [81]; EMBER‑3 [82], SERENA‑2 [83]; BYLieve [84]; SOLAR‑1 [73], CAPitello-291 [72]
Abb. 3
Abb. 3
Wirksamkeit von 2L+ Therapien beim ESR1-mutierten HR+/HER2− mBC nach vorangegangener CDK4/6i-Therapie. EMERALD [77]; EMBER‑3 [82]; SERENA‑2 [83]; TRINITI‑1 [94]; MAINTAIN [58]; BYLieve [95]
Abb. 4
Abb. 4
Kandidatin für ET ± zielgerichtete Therapie in der 2L nach Progress nach AI + CDK4/6i laut ESMO Metastatic Breast Cancer Living Guidelines (V1.2, April 2025) [11]
Abb. 5
Abb. 5
Keine Kandidatin für ET ± zielgerichtete Therapie in der 2L nach Progress nach AI + CDK4/6i laut ESMO Metastatic Breast Cancer Living Guidelines (V1.2, April 2025) [11]
See this image and copyright information in PMC

References

    1. Finn RS, et al. N Engl J Med. 2016;375:1925–36. - PubMed
    1. Turner NC, et al. N Engl J Med. 2015;373:209–19. - PubMed
    1. Finn RS, et al. Lancet Oncol. 2015;16:25–35.
    1. Hortobagyi GN, et al. N Engl J Med. 2016;375:1738–48. - PubMed
    1. Cristofanilli M, et al. Lancet Oncol. 2016;17:425–39.

LinkOut - more resources